References

1. PA Wayne et al., "Biochemical Tumor Marker Testing. CLSI guideline C65," Clinical and Laboratory Standards Institute (2026). Available at: https://clsi.org/
2. S Kumar et al., "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma," Lancet Oncol, 15, 12 (2014). PMID: 25439696.
3. M Roach et al., "Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference," Int J Radiat Oncol Biol Phys, 65, 4 (2006). PMID: 16798415.
4. T Dejoie et al., "Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma," Blood, 128, 25 (2016). PMID: 27729323.
5. CM Sturgeon et al., "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements," Clin Chem, 54, 8 (2008). PMID: 18606634.
6. A Heidenreich et al., "EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer," Eur Urol, 65, 1 (2014). PMID: 24321502.
7. C Onal et al., "Plasma citrulline levels predict intestinal toxicity in patients treated with pelvic radiotherapy," Acta Oncol, 50, 8 (2011). PMID: 21864050.